Boston Scientific Surges to 131st in Trading Volume with 7.34 Billion Turnover

On May 27, 2025, Boston Scientific (BSX) experienced a significant increase in trading volume, with a total turnover of 7.34 billion, marking a 34.89% rise from the previous day. This surge placed Boston Scientific at the 131st position in terms of trading volume for the day. The stock price of Boston Scientific also saw a 1.60% increase, marking the second consecutive day of gains.

Boston Scientific recently unveiled data from the Early ACURATE PRIME Registry, which assesses the Acurate Prime aortic valve system. This registry provides the first extensive, real-world clinical data on the company's latest transcatheter aortic valve replacement (TAVR) device since its approval and launch in Europe last year. The registry, comprising 517 patients across 12 European sites, reported a technical success rate of 98.6% and a 30-day device success rate of 96.4%. Additionally, the overall new permanent pacemaker implantation rate was 9.8%, with a 30-day postimplantation aortic valve area of 2.6 cm2. Dr. Andreas Rück, Head of the Transcatheter Aortic Valve Implantation program at Karolinska University Hospital in Stockholm, Sweden, presented these findings at the EuroPCR 2025 conference in Paris.

The registry data also highlighted favorable core-lab adjudicated hemodynamic results at 30 days, including a 1.2% rate of severe or moderate paravalvular leakage and an aortic mean gradient of 7.2 mm Hg. These positive outcomes underscore the effectiveness and safety of the Acurate Prime TAVR system, which is designed to restore normal blood flow through the narrowed aortic valve in patients with severe aortic stenosis, regardless of their risk level.